NCT06815991View on ClinicalTrials.gov

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions
Healthy Adults
Interventions
DRUG

MIB-725

MIB-725 is a modified precursor of the NAD+ biosynthetic pathway.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Metro International Biotech, LLC

INDUSTRY